Clinical Trial Update: Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daratumumab with bortezomib and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)

Snippet

Sponsor: Singapore General Hospital | Conditions: Multiple Myeloma, Myeloma | Phase 2 | Status: UNKNOWN